Wegovy and other GLP-1 medications have become extremely popular over the past few years. Novo Nordisk (which makes both ...
Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical ...
Some patients taking weight-loss drugs, including popular GLP-1 treatments like Ozempic (NVO) and Wegovy, reported reducing ...
Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy ...
Zepbound outperformed Wegovy for weight loss in a new clinical trial funded by Eli Lilly & Co., Zepbound's maker.
The Biden administration is looking to expand access to anti-obesity GLP-1 drugs like Ozempic and Wegovy for people who have ...
In 2021, the U.S. Food and Drug Administration approved Wegovy for "chronic weight management ... a health policy research ...
Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...
Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo ...
The proposed buyout of contract drug manufacturer Catalent won’t raise competition concerns, the European Commission said.